Subchondral Solutions received FDA 510(k) clearance to market the fenestrated, cannulated S4 Screw System™ to treat osteochondral fractures.
S4 is the company’s first FDA-cleared device in its platform that will address joint pain and damage with biomechanical and bioactive implants. The approach focuses on early biomechanical support for the entire bone/cartilage unit. Subchondral Solutions was established in California in 2014.
Subchondral Solutions received FDA 510(k) clearance to market the fenestrated, cannulated S4 Screw System™ to treat osteochondral fractures.
S4 is the company's first FDA-cleared device in its platform that will address joint pain and damage with biomechanical and bioactive implants. The approach focuses on early...
Subchondral Solutions received FDA 510(k) clearance to market the fenestrated, cannulated S4 Screw System™ to treat osteochondral fractures.
S4 is the company’s first FDA-cleared device in its platform that will address joint pain and damage with biomechanical and bioactive implants. The approach focuses on early biomechanical support for the entire bone/cartilage unit. Subchondral Solutions was established in California in 2014.
Copy to clipboard 
